EP4232046A4 - Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate - Google Patents
Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate Download PDFInfo
- Publication number
- EP4232046A4 EP4232046A4 EP21803262.1A EP21803262A EP4232046A4 EP 4232046 A4 EP4232046 A4 EP 4232046A4 EP 21803262 A EP21803262 A EP 21803262A EP 4232046 A4 EP4232046 A4 EP 4232046A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- dissolution rate
- compositions prepared
- milling method
- dry milling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title 1
- 229960000590 celecoxib Drugs 0.000 title 1
- 238000004090 dissolution Methods 0.000 title 1
- 238000009837 dry grinding Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2020/17034A TR202017034A2 (en) | 2020-10-26 | 2020-10-26 | PHARMACEUTICAL COMPOSITIONS PREPARED BY THE DRY GRINDING METHOD AND CONTAINING SELECOXIB WITH INCREASED DISORDER |
| PCT/TR2021/050619 WO2021230849A1 (en) | 2020-10-26 | 2021-06-17 | Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4232046A1 EP4232046A1 (en) | 2023-08-30 |
| EP4232046A4 true EP4232046A4 (en) | 2023-11-08 |
Family
ID=78524739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21803262.1A Pending EP4232046A4 (en) | 2020-10-26 | 2021-06-17 | Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4232046A4 (en) |
| TR (1) | TR202017034A2 (en) |
| WO (1) | WO2021230849A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121321A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
| CN102988296A (en) * | 2011-09-08 | 2013-03-27 | 江苏恒瑞医药股份有限公司 | Celecoxib solid dispersion and preparation method thereof |
| CN110840850A (en) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | Celecoxib freeze-dried orally disintegrating tablet with high bioavailability and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2759125C (en) * | 2009-04-24 | 2017-08-15 | Iceutica Pty Ltd | A novel formulation of indomethacin |
-
2020
- 2020-10-26 TR TR2020/17034A patent/TR202017034A2/en unknown
-
2021
- 2021-06-17 EP EP21803262.1A patent/EP4232046A4/en active Pending
- 2021-06-17 WO PCT/TR2021/050619 patent/WO2021230849A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010121321A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
| CN102988296A (en) * | 2011-09-08 | 2013-03-27 | 江苏恒瑞医药股份有限公司 | Celecoxib solid dispersion and preparation method thereof |
| CN110840850A (en) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | Celecoxib freeze-dried orally disintegrating tablet with high bioavailability and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232046A1 (en) | 2023-08-30 |
| TR202017034A2 (en) | 2021-09-21 |
| WO2021230849A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3914252A4 (en) | Pharmaceutical compositions of nilotinib | |
| EP3746076A4 (en) | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent | |
| EP4003369A4 (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| SG11202011886TA (en) | PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF | |
| EP3604301A4 (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | |
| EP3880688A4 (en) | Oligosaccharide preparations and compositions | |
| EP3896062A4 (en) | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound | |
| EP4035657A4 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
| EP3312175A4 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| EP3980412A4 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| EP4134366A4 (en) | 3-azabicycloalkyl derivative and pharmaceutical composition containing same | |
| EP3762392A4 (en) | Thienopyridine derivatives and pharmaceutical composition comprising same | |
| EP3785708A4 (en) | Film-forming composition containing surfactant or surfactant and salt as whitening agent | |
| EP3825308A4 (en) | Compound, composition, and use thereof in preparation of drug | |
| EP3743074A4 (en) | Composition and method for reducing thrombocytopenia via the administration of plinabulin | |
| EP3694330A4 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| EP4073071A4 (en) | Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives | |
| EP3725297A4 (en) | Oral pharmaceutical composition containing pemetrexed and production method thereof | |
| EP3694331A4 (en) | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| EP4023227A4 (en) | Pharmaceutical composition and application thereof | |
| EP3866767A4 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| IL285421A (en) | Indazolyl-isoxazole derivatives, their preparation and pharmaceutical compositions containing them | |
| EP3982942A4 (en) | Drug delivery methods and compositions | |
| EP3929198A4 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| EP3908251A4 (en) | Pharmaceutical delivery compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230427 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231010 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/14 20060101ALI20231004BHEP Ipc: A61K 31/415 20060101ALI20231004BHEP Ipc: A61K 31/635 20060101AFI20231004BHEP |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |